Journey Medical (DERM)

Search documents
Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
Globenewswire· 2025-01-23 13:30
Core Viewpoint - Journey Medical Corporation is preparing for the commercial launch of Emrosi™, an FDA-approved treatment for rosacea, with a focus on establishing it as a new oral standard of care for adult patients [1][2]. Company Overview - Journey Medical Corporation is a commercial-stage pharmaceutical company that specializes in marketing FDA-approved prescription products for dermatological conditions [9]. - The company currently markets seven branded and two generic products aimed at treating common skin conditions [9]. - Founded by Fortress Biotech, Inc., Journey Medical is located in Scottsdale, Arizona [9]. Product Information - Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) was approved by the FDA in November 2024 for treating inflammatory lesions of rosacea in adults [1]. - The product was developed in collaboration with Dr. Reddy's Laboratories Ltd. [1]. Launch Plans - The management team will host a conference call on February 5, 2025, to discuss the commercial launch plan for Emrosi, including pre-commercial activities and launch timing [1][3]. - The company is finalizing the manufacturing of launch quantities for the U.S. market and preparing its dermatology-focused sales force for the rollout [2]. Market Context - Rosacea is a chronic skin condition affecting over 16 million Americans and approximately 415 million people worldwide, primarily seen in adults aged 30 to 50 [8]. - The condition significantly impacts patients' self-confidence and social interactions, with many reporting adverse effects on their professional lives [8].
Journey Medical Corporation (DERM) Reports Q3 Loss, Tops Revenue Estimates
ZACKS· 2024-11-12 23:26
Journey Medical Corporation (DERM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to earnings of $0.80 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 29.41%. A quarter ago, it was expected that this company would post a loss of $0.15 per share when it actually produced a loss of $0.17, delivering a surprise of -13.33%.Over the last four quarters, the com ...
Journey Medical (DERM) - 2024 Q3 - Quarterly Report
2024-11-12 21:06
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-41063 JOURNEY MEDICAL CORPORATION (Exact name of registrant as specified in its chart ...
Journey Medical (DERM) - 2024 Q3 - Quarterly Results
2024-11-12 21:05
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 Journey Medical Corporation (Exact Name of Registrant as Specified in Charter) | --- | --- | --- | |------------------------------------|------------------------------|-----------------------| | Delaware | 001-41063 | 47-1879539 | | (State or Other Jurisdiction | (Commission Fi ...
Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
GlobeNewswire News Room· 2024-11-12 21:01
U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of 2025 Total revenues for the third quarter ended September 30, 2024 were $14.6 million SCOTTSDALE, Ariz., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on the selling and ...
Journey Medical (DERM) Soars 7.3%: Is Further Upside Left in the Stock?
ZACKS· 2024-11-04 13:21
Journey Medical Corporation (DERM) shares ended the last trading session 7.3% higher at $6.17. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 8.6% loss over the past four weeks.The FDA is slated to communicate its decision regarding Journey Medical’s regulatory filing for DFD-29, for the treatment of inflammatory lesions and erythema (redness) of rosacea in adults, today. The stock price rally is likely in anticip ...
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
GlobeNewswire News Room· 2024-11-04 12:00
SCOTTSDALE, Ariz., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the FDA has approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg), formerly referred to as DFD-29, for the treatment of infl ...
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference
GlobeNewswire News Room· 2024-10-25 12:30
Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline 40 mg Capsules (Oracea®) in Healthy Subjects With its modified-release formulation, DFD-29 (40 mg) provides higher dermal concentration than doxycycline from Day 1 onward at a similar dose, expected to translate into a clinically meaningful impact for treating patients with rosacea New Drug Application for DFD-29 under review by FDA with PDUFA goal date ...
Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
GlobeNewswire News Room· 2024-10-03 12:30
SCOTTSDALE, Ariz., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that members of Journey Medical's management team will attend one-on-one meetings at the 3rd Annual ROTH Healthcare Opportunities ...
Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference
GlobeNewswire News Room· 2024-09-09 12:30
SCOTTSDALE, Ariz., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, President and Chief Executive Officer, will attend one-on-one meetings at the Lake Street Capital Markets 8 ...